Management of Postoperative Atrial Fibrillation and Subsequent Outcomes in Contemporary Patients Undergoing Cardiac Surgery: Insights From the Society of Thoracic Surgeons CAPS‐Care Atrial Fibrillation Registry
Background Postoperative atrial fibrillation (POAF) is a well‐recognized complication of cardiac surgery; however, its management remains a challenge, and the implementation and outcomes of various strategies in clinical practice remain unclear. Hypothesis We hypothesize that treatment for POAF is v...
Saved in:
Published in: | Clinical cardiology (Mahwah, N.J.) Vol. 37; no. 1; pp. 7 - 13 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York
Wiley Periodicals, Inc
01-01-2014
John Wiley & Sons, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Postoperative atrial fibrillation (POAF) is a well‐recognized complication of cardiac surgery; however, its management remains a challenge, and the implementation and outcomes of various strategies in clinical practice remain unclear.
Hypothesis
We hypothesize that treatment for POAF is variable, and that it is associated with particular morbidity and mortality following cardiac surgery.
Methods
We compared patient characteristics, operative procedures, postoperative management, and outcomes between patients with and without POAF following coronary artery bypass grafting (CABG) in the Society of Thoracic Surgeons multicenter Contemporary Analysis of Perioperative Cardiovascular Surgical Care (CAPS‐Care) registry (2004–2005).
Results
Of 2390 patients who underwent CABG, 676 (28%) had POAF. Compared with patients without POAF, those with POAF were older (median age 74 vs 71 years, P < 0.0001) and more likely to have hypertension (86% vs 83%, P = 0.04) and impaired renal function (median estimated glomerular filtration rate 56.9 vs 58.6 mL/min/1.73 m2, P = 0.0001). A majority of patients with POAF were treated with amiodarone (77%) and β‐blockers (68%); few (9.9%) underwent cardioversion. Patients with POAF were more likely to experience complications (57% vs 41%, P < 0.0001), including acute limb ischemia (1.0% vs 0.4%, P = 0.03), stroke (4.0% vs 1.9%, P = 0.002), and reoperation (13% vs 7.9%, P < 0.0001). Length of stay (median 8 days vs 6 days, P < 0.0001), in‐hospital mortality (6.8% vs 3.7%, P = 0.001), and 30‐day mortality (7.8 vs 3.9, P < 0.0001) were all worse for patients with POAF. In adjusted analyses, POAF remained associated with increased length of stay following surgery (adjusted ratio of the mean: 1.27, 95% confidence interval: 1.2‐1.34, P < 0.0001).
Conclusions
Postoperative AF is common following CABG, and such patients continue to have higher rates of postoperative complications. Postoperative AF is significantly associated with increased length of stay following surgery. |
---|---|
Bibliography: | Additional Supporting Information may be found in the online version of this article. The authors have no other funding, financial relationships, or conflicts of interest to disclose. This analysis was funded by a grant from Janssen Scientific Affairs LLC, Raritan NJ. The study design, analysis plan, statistical analysis, and drafting of the manuscript were performed independently of the funding entity. Each author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. Dr. Steinberg was funded by National Institutes of Health T‐32 training grant No. 5 T32 HL 7101‐37. The following relationships exist related to this article: Dr. Steinberg received minor educational support from Medtronic; Dr. Zhao and Mr. He have no disclosures; Dr. Piccini receives research funding from Johnson & Johnson and provides consulting to Forest Laboratories, Janssen Pharmaceuticals, and Medtronic. Dr. Mills and Dr. Klaskala are full‐time employees of Janssen Research & Development, LLC; a detailed description of Dr. Piccini's, Dr. Hernandez's, and Dr. Peterson's disclosures can be found at . https://dcri.org/about‐us/conflict‐of‐interest This analysis was funded by a grant from Janssen Scientific Affairs LLC, Raritan NJ. The study design, analysis plan, statistical analysis, and drafting of the manuscript were performed independently of the funding entity. Each author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. Dr. Steinberg was funded by National Institutes of Health T‐32 training grant No. 5 T32 HL 7101‐37. The following relationships exist related to this article: Dr. Steinberg received minor educational support from Medtronic; Dr. Zhao and Mr. He have no disclosures; Dr. Piccini receives research funding from Johnson & Johnson and provides consulting to Forest Laboratories, Janssen Pharmaceuticals, and Medtronic. Dr. Mills and Dr. Klaskala are full‐time employees of Janssen Research & Development, LLC; a detailed description of Dr. Piccini's, Dr. Hernandez's, and Dr. Peterson's disclosures can be found at https://dcri.org/about‐us/conflict‐of‐interest. |
ISSN: | 0160-9289 1932-8737 |
DOI: | 10.1002/clc.22230 |